Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Formycon AG (FYB.DE)
EUR18.16
-0.10 (-0.55%)
DE XETRA Healthcare Biotechnology
Address
Fraunhoferstrasse 15 82152
Planegg, DE
Planegg, DE
CEO
Stefan Glombitza
Website
formycon.com
IPO
2011-01-04
ISIN DE000A1EWVY8
Also trades on
Deutsche Börse · FYB.DE (EUR)
London Stock Exchange · 0W4N.L (EUR)
Description
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR18.16
-0.10 (-0.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10.1K
Beta
0.72
Float Shares
8.00M
Free Float %
45.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.10% | +11.88% | +24.86% | -1.53% | -6.80% | -13.41% | -4.64% | -69.87% | -62.83% | +4.68% | +153.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
18.16
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.07
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-36.2% Q4'25: +4.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+49.0% ★ Q4'25: -112.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+14.7% Q4'25: +11.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-66.0% Q4'25: +4.9% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-8.6% ★ Q4'25: +1.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q4'25: +10.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.92× Q4'25: 0.16× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 1 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
138.4K
est: 1.52M (-90.9%)
|
276.2K
est: 482.1K (-42.7%)
|
12.59M
est: 13.02M (-3.4%)
|
16.92M
est: 19.50M (-13.2%)
|
19.53M
est: 19.00M (+2.8%)
|
29.00M
est: 25.00M (+16.0%)
|
42.99M
est: 38.25M (+12.4%)
|
33.16M
est: 36.00M (-7.9%)
|
34.23M
est: 38.25M (-10.5%)
|
36.61M
est: 40.50M (-9.6%)
|
42.50M
est: 40.83M (+4.1%)
|
77.70M
est: 60.80M (+27.8%)
|
69.67M
est: 60.10M (+15.9%)
|
44.48M
est: 53.68M (-17.1%)
|
64.25M
56.19M – 72.80M
+19.7% YoY
|
107.80M
62.50M – 179.20M
+67.8% YoY
|
121.00M
81.41M – 180.93M
+12.2% YoY
|
159.66M
107.42M – 238.73M
+31.9% YoY
|
| EBITDA |
-1.98M
est: 437.7K (-551.3%)
|
-6.63M
est: -592.2K (-1,020.3%)
|
1.94M
est: -179.08M (+101.1%)
|
1.60M
est: 2.67M (-40.2%)
|
-3.34M
est: 1.71M (-295.9%)
|
-751.5K
est: -4.58M (+83.6%)
|
8.02M
est: -1.21M (+763.1%)
|
-1.36M
est: 7.67M (-117.8%)
|
-5.63M
est: -1.51M (-271.9%)
|
-12.42M
est: -1.35M (-821.7%)
|
51.53M
est: -1.75M (+3,045.1%)
|
81.05M
est: 18.81M (+330.8%)
|
-4.10M
est: 18.34M (-122.3%)
|
-2.44M
est: 16.61M (-114.7%)
|
19.88M
17.39M – 22.52M
+19.7% YoY
|
33.35M
19.34M – 55.45M
+67.8% YoY
|
37.44M
25.19M – 55.98M
+12.2% YoY
|
49.40M
33.24M – 73.87M
+31.9% YoY
|
| EBIT |
-2.37M
est: 129.6K (-1,928.4%)
|
-7.74M
est: -779.0K (-893.2%)
|
869.5K
est: -209.06M (+100.4%)
|
604.2K
est: 1.21M (-50.0%)
|
-4.04M
est: 583.1K (-792.7%)
|
-1.54M
est: -5.55M (+72.3%)
|
7.13M
est: -2.23M (+419.8%)
|
-2.27M
est: 6.85M (-133.2%)
|
-6.54M
est: -2.43M (-168.7%)
|
-14.03M
est: -2.17M (-547.1%)
|
49.67M
est: -2.82M (+1,864.0%)
|
79.15M
est: -530.4K (+15,023.0%)
|
-143.16M
est: -517.1K (-27,586.2%)
|
-29.37M
est: -468.3K (-6,171.8%)
|
-560.5K
-635.0K – -490.2K
-19.7% YoY
|
-940.4K
-1.56M – -545.2K
-67.8% YoY
|
-1.06M
-1.58M – -710.2K
-12.2% YoY
|
-1.39M
-2.08M – -937.1K
-31.9% YoY
|
| Net Income |
-2.40M
est: -8.61M (+72.2%)
|
-7.74M
est: -760.0K (-918.5%)
|
860.3K
est: -209.06M (+100.4%)
|
577.5K
est: 1.19M (-51.7%)
|
-4.07M
est: 632.1K (-743.2%)
|
-1.58M
est: -5.55M (+71.5%)
|
7.10M
est: -2.29M (+409.5%)
|
-2.29M
est: 6.82M (-133.6%)
|
-6.73M
est: -2.46M (-174.0%)
|
-13.29M
est: -2.19M (-507.6%)
|
35.99M
est: -42.24M (+185.2%)
|
75.80M
est: 63.90M (+18.6%)
|
-125.67M
est: -15.06M (-734.6%)
|
-64.70M
est: -64.70M (+0.0%)
|
-12.00M
-16.26M – -5.69M
+81.5% YoY
|
22.53M
19.40M – 25.66M
+287.8% YoY
|
37.70M
18.58M – 53.15M
+67.3% YoY
|
54.06M
31.07M – 88.87M
+43.4% YoY
|
| SGA |
567.7K
est: 355.2K (+59.8%)
|
2.91M
est: 112.5K (+2,486.2%)
|
2.89M
est: 3.04M (-4.7%)
|
3.86M
est: 4.02M (-3.9%)
|
5.12M
est: 4.23M (+21.1%)
|
6.33M
est: 6.98M (-9.4%)
|
7.93M
est: 9.17M (-13.6%)
|
-31.41M
est: 7.62M (-512.2%)
|
5.95M
est: 9.74M (-38.9%)
|
7.13M
est: 8.67M (-17.8%)
|
12.89M
est: 11.26M (+14.4%)
|
14.57M
est: 17.62M (-17.3%)
|
21.39M
est: 17.18M (+24.5%)
|
20.31M
est: 15.56M (+30.5%)
|
18.62M
16.29M – 21.10M
+19.7% YoY
|
31.25M
18.12M – 51.94M
+67.8% YoY
|
35.07M
23.60M – 52.44M
+12.2% YoY
|
46.28M
31.14M – 69.20M
+31.9% YoY
|
| EPS |
-0.24
est: -0.49 (+51.3%)
|
-0.77
est: -0.88 (+12.9%)
|
0.10
est: 0.02 (+393.6%)
|
0.06
est: 0.11 (-42.2%)
|
-0.45
est: -0.23 (-95.7%)
|
-0.17
est: -0.05 (-240.0%)
|
0.75
est: 0.59 (+27.1%)
|
-0.23
est: -0.27 (+14.0%)
|
-0.66
est: -0.28 (-138.9%)
|
-1.20
est: -1.22 (+1.2%)
|
2.62
est: 2.49 (+5.1%)
|
4.76
est: 3.84 (+24.0%)
|
-7.18
est: -0.77 (-834.5%)
|
-3.66
est: -3.28 (-11.6%)
|
-0.56
-0.92 – -0.32
+82.9% YoY
|
1.27
1.10 – 1.45
+326.8% YoY
|
1.83
1.05 – 3.01
+44.1% YoY
|
3.06
1.76 – 5.03
+67.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-16.46M
OE per share TTM
-0.97
Owner's Yield
-4.12%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
20.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Value ETF AVDV | 0.01% | 1.55M | 0.36% |
| 2 | Avantis International Equity ETF AVDE | 0.00% | 81.3K | 0.23% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-117.5K
Shares Outstanding
17.67M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stefan Glombitza | Chief Executive Officer, Chief Operating Officer & Chair of the Executive Board | 612.3K | — |
| Enno Spillner | Chief Financial Officer & Member of the Executive Board | 560.9K | male |
| Nicola Mikulcik | Chief Business Officer & Member of the Executive Board | 393.8K | female |
| Andreas Seidl | Chief Scientific Officer & Member of the Executive Board | 339.5K | — |
| Nicolas Combe | Co-Founder | — | — |
| Sabrina Muller | Director of Investor Relations & Corporate Communications | — | — |
| Friedrich-Wilhelm Steinweg | Co-Founder | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FYB.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
